|
||||
|
Product trade name: Optipar
Pharmaceutical active ingredients containing related brand and generic drugs, medications or other health care products: Optipar available forms, composition, doses: Optipar destination | category: Indications and usages, anatomical therapeutic chemical and diseases classification codes: Pharmaceutical companies, researchers, developers, manufacturers, distributors and suppliers: Online pharmacy, drugstores, pharma, health and beauty shops selling this or related pharmaceutical products: There is an additional general information about this medication active ingredient paroxetine: Pharmacological action Optipar is an antidepressant, selective serotonin reuptake inhibitor. This medication has a bicyclic structure distinct from the structures of other known antidepressants. Paroxetine has antidepressant and anxiolytic effects when expressed enough incentive (activated) effect. Antidepressant (thymoleptic) action is related to the ability of paroxetine selectively block the reuptake of serotonin presynaptic membrane than is caused by increase of free content of this neurotransmitter in the synaptic cleft and enhancement of its activity in the CNS. Effect on the m-cholinergic receptors, alpha- and beta-adrenergic receptors is only slightly which determines the extremely weak intensity of the side effects. Pharmacokinetics After oral administration Optipar is well absorbed from the gastrointestinal tract. Ingestion did not affect absorption. Css is set to the 7-14 day since the start of therapy. The major metabolites of paroxetine are polar and conjugated products of oxidation and methylation. Due to the low pharmacological activity of metabolites their impact on therapeutic efficacy is unlikely. T1/2 on average is 16-24 hours. Less than 2% excreted in the urine in unchanged form, the rest - in the form of metabolites or urine (64%), or bile. Excretion of paroxetine is biphasic. With long-term continuous using of this drug pharmacokinetic parameters do not change. Why is Optipar prescribed? Endogenous, neurotic and reactive depression. Dosage and administration When Optipar administered orally an initial dose is 10-20 mg / day. If necessary, depending on the evidence, the dose was increased to 40-60 mg / day. Increasing the dose spend gradually on 10 mg with intervals of 1 week. Frequency of admission is 1 time / day. The treatment of long-term. Treatment's efficacy is assessed after 6-8 weeks. For elderly and debilitated patients, as well as renal impairment and hepatic the initial dose is 10 mg / day, the maximum dose is 40 mg / day. Optipar side effects, adverse reactions CNS: rarely (when used in doses more than 20 mg) - drowsiness, tremor, fatigue, insomnia. Digestive system: rarely (when used in doses more than 20 mg) - nausea, dry mouth, and in some cases constipation. Other: rarely (when used in doses more than 20 mg) - increased sweating, ejaculation disorders. Optipar contraindications Simultaneous treatment with MAO inhibitors, and the period up to 14 days after their withdrawal, hypersensitivity to paroxetine. Restrictions for using Angle-closure glaucoma, prostate adenoma, pregnancy (the appointment is permissible only if absolutely necessary) and breastfeeding. Using during pregnancy and breastfeeding Category effects on the fetus by FDA - C. Special instructions Stop taking of Optipar should be gradually reducing the dose to avoid withdrawal syndrome, which manifests itself dizziness, nausea, vomiting, insomnia, confusion, increased sweating. There is contraindicated drinking alcohol during the treatment with paroxetine. Be wary of over 14 days after taking of MAO inhibitors, gradually increasing the dose. MAO inhibitors should not be administered within 2 weeks after complete withdrawal of paroxetine. Simultaneous administration with drugs that inhibit the metabolism of liver enzymes, Optipar should be used in the smallest recommended doses. In simultaneous use with drugs that induce the metabolism of enzymes it does not required any changes in the initial doses of paroxetine. Be wary of using paroxetine with lithium therapy (recommended to monitor the lithium concentration in blood plasma) and oral anticoagulants. There was not found carcinogenic and mutagenic properties of paroxetine in experimental studies. Use Optipar with caution in patients whose activities are connected with the necessity of high concentration of attention and quickness of psychomotor reactions. Optipar drug interactions Simultaneous administration of Optipar with: Optipar in case of emergency / overdose Symptoms: nausea, vomiting, drowsiness, sinus tachycardia, dilated pupils, etc. Treatment: symptomatic; to remove from the stomach not absorbed part of this drug it is necessary to induce vomiting or gastric lavage.
Comments
|
|
|||
|
||||